Baxter (BAX) Q1 2026 earnings review
Turnaround Stalls as Margins Compress and Organic Growth Turns Negative
Baxter's first quarter under its new streamlined post-Kidney Care structure shows a business still searching for the bottom. While reported sales grew 3%, organic revenue actually contracted 1%, dragged down by the ongoing Novum IQ pump shipment hold and weakness in Injectables. The real story, however, is the collapsing profitability: Adjusted EPS plunged 35% YoY to $0.36, and adjusted operating margins shed nearly 400 basis points. Management points to the new 'Baxter GPS' operating system for future continuous improvement, but the current reality is dominated by higher manufacturing costs, lower absorption, and tariff headwinds. FY26 guidance for flat organic growth and an earnings decline was reiterated, leaving investors waiting for tangible signs of a fundamental recovery.
🐂 Bull Case
Advanced Surgery (+10% organic) and Drug Compounding (+20% organic) are providing crucial growth offsets to the struggling core divisions.
Free cash flow from continuing operations turned positive to $76M, a meaningful recovery from a $221M burn in the same period last year, showing early signs of working capital discipline.
🐻 Bear Case
Adjusted operating margin collapsed to 11.0% from 14.9% a year ago. The toxic combination of tariffs, lower manufacturing absorption, and unfavorable product mix is structurally eroding profitability.
The Infusion Therapies segment organic sales fell 5%. The prolonged ship and install hold on the Novum IQ LVP pump continues to paralyze the division and risks permanent customer attrition.
⚖️ Verdict: 🔴
Bearish. Top-line organic contraction and severe margin compression overshadow the isolated segment bright spots. The turnaround plan is highly back-half weighted and carries significant execution risk.
Key Themes
Profitability Under Severe Pressure
Margin compression is Decelerating rapidly. Adjusted Gross Margin fell to 36.8% from 41.8% a year ago, while Adjusted Operating Margin dropped to 11.0% from 14.9%. Management attributed this to an unfavorable expense timing shift, higher tariffs, and higher manufacturing costs (lower absorption). This broad-based cost pressure heavily contradicts management's narrative of continuous improvement and 'stabilizing the business.'
Novum IQ Hold Anchors MPT Segment
The Infusion Therapies & Technologies division is Reversing, with organic sales dropping 5%. This is the direct result of the prolonged shipment and installation hold of the Novum IQ LVP. Without resolution, Baxter is effectively frozen out of the large volume pump replacement cycle, losing ground to competitors.
Advanced Surgery & Drug Compounding Growth Engines
In a quarter of top-line misses, two segments are Accelerating. Drug Compounding surged 20% organically to $320M, while Advanced Surgery grew 10% organically to $304M. These divisions are doing the heavy lifting to prevent a steeper consolidated revenue decline and are benefiting from sustained global demand.
Injectables & Anesthesia Collapse
A massive laggard emerged in Pharmaceuticals: Injectables & Anesthesia sales collapsed 13% organically. This reflects a continuation of the 'IV push' protocol shifts in hospitals, highlighting an unfavorable product mix shift that directly pressures segment profitability.
Baxter GPS Rollout
CEO Andrew Hider is leaning heavily into the newly expanded 'Baxter Growth and Performance System' (GPS). Management launched over 230 continuous improvement initiatives in Q1 alone. While a positive step for culture, the deep 35% YoY adjusted EPS drop indicates these initiatives will take significant time to flow through to the bottom line.
Other KPIs
Reversing to positive. A notable bright spot, improving from negative $221 million in 25Q1. This indicates better working capital management and disciplined capital expenditure ($137M vs $122M YoY) despite the massive earnings drop.
Stable YoY (23.2% in 25Q1). While gross margins collapsed, operating expenses were managed relatively well. Absolute adjusted SG&A dollars rose only slightly to $614M from $608M.
Guidance
Decelerating. The midpoint of $1.95 implies a ~14% decline from FY25's $2.27 continuing operations result. Reiteration of this weak outlook confirms management's expectation that margin pressures and the Novum pump headwind will persist for the vast majority of the year.
Decelerating. Dropping from 3% operational growth in 2025 to flat in 2026. This underscores the structural headwinds in IV Solutions conservation and the lack of infusion pump revenue.
Key Questions
Novum IQ Resolution Timeline
What are the specific remaining hurdles with the FDA regarding the Novum IQ LVP hold, and have you observed any material customer contract cancellations due to the delay?
Margin Bridge Mechanics
Adjusted operating margins fell from 14.9% to 11.0%. Can you quantify exactly how much of this 390 bps compression was due to the 'timing shift in expense recognition' versus structural issues like lower factory absorption?
Injectables Floor
With Injectables & Anesthesia down 13% organically, where do you see the floor for hospital protocol shifts toward IV push? Is this a permanent demand destruction event for the legacy portfolio?